Relacorilant (Lifyorli)

Small molecule

Also known as CORT125134

Approvedregulatory verdict

Evidence outlook

Approved: Ovarian Cancer (label: platinum-resistant, with nab-paclitaxel, after one to three prior regimens)

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Cushing's Syndrome · Phase 3 · under FDA review

Company guidance: regulatory decision expected fourth quarter of 2026 (Corcept Therapeutics, 18 Sep 2026). “In this press release, forward-looking statements include statements concerning: relacorilant’s safety profile and potential as a treatment for patients with platinum-resistant ovarian cancer; the anticipated timing and outcome of the EC’s review of the CHMP opinion, including the potential for the EC to approve our marketing application in the fourth quarter of 2026; and Corcept’s intent to make the benefits of glucocorticoid receptor antagonism available to patients in the EU.” Source ↗

Company guidance: data expected next year (Corcept Therapeutics, 29 Jul 2026). “STELLA – Initiated Phase 2 trial of relacorilant plus nab-paclitaxel in 50 patients with cervical cancer (received one or two prior lines of therapy), conducted in collaboration with ARCAGY-GINECO – Results expected by the end of next year” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
Cushing's Syndrome
Other / comorbidity
NCT04329949 · Corcept Therapeutics
2020-06-30 – 2022-03-25 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
Phase 2 (7)
Cushing's Syndrome
NCT03604198 · Corcept Therapeutics
2018-05-07 – 2026-12 · Cushing Syndrome
What this study did
NCT02804750 · Corcept Therapeutics
2016-06 – 2018-09 · Cushing's Syndrome
What this study did
Ovarian Cancer
NCT06906341 · Corcept Therapeutics
2025-04-11 – 2028-08 · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
What this study did
NCT03776812 · Corcept Therapeutics
2019-04-05 – 2023-07-12 · Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
What this study did
Other / comorbidity
NCT07763496 · ARCAGY/ GINECO GROUP
2026-10 – 2030-12 · Recurrent or Metastatic Cervical Cancer
What this study did
NCT05726292 · University of Chicago
2025-01-06 – 2028-04-01 · Prostate Cancer, Prostate Adenocarcinoma
What this study did
NCT07259317 · Corcept Therapeutics
2026-01-27 – 2027-09 · Adenocarcinoma, Carcinoma, Pancreatic Ductal
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT07925801 · The University of Texas Health Science Center at San Antonio
2026-12-01 – 2029-12-15 · Type 2 Diabetes, Hypercortisolism
What this study did
NCT02762981 · Corcept Therapeutics
2016-05-23 – 2020-09-12 · Solid Tumors
What this study did
Phase 1 (14)
Cushing's Syndrome
NCT05347979 · Corcept Therapeutics
2022-05-25 – 2022-07-19 · Cushing Syndrome, Neoplasms
What this study did
Other / comorbidity
NCT03674814 · University of Chicago
2018-10-23 – 2024-06-10 · Prostate Cancer
What this study did
NCT04373265 · Corcept Therapeutics
2020-09-30 – 2024-01-12 · Adrenocortical Carcinoma
What this study did
NCT04795479 · Corcept Therapeutics
2021-01-22 – 2021-07-13 · Healthy
What this study did
NCT06094725 · Corcept Therapeutics
2020-01-06 – 2020-12-14 · Hepatic Impairment
What this study did
NCT06094738 · Corcept Therapeutics
2020-09-19 – 2020-11-16 · Healthy
What this study did
NCT03512548 · Corcept Therapeutics
2018-04-10 – 2019-08-23 · Healthy
What this study did
NCT03540836 · Corcept Therapeutics
2018-05-24 – 2018-07-25 · Healthy
What this study did
NCT03457597 · Corcept Therapeutics
2018-03-06 – 2018-04-28 · Healthy
What this study did
NCT03442621 · Corcept Therapeutics
2018-01-16 – 2018-03-09 · Healthy, Food-drug Interaction
What this study did
NCT06094790 · Corcept Therapeutics
2017-05-18 – 2017-11-15 · Healthy
What this study did
NCT03067376 · Corcept Therapeutics
2016-08 – 2016-09 · Healthy
What this study did
NCT06094712 · Corcept Therapeutics
2016-04-07 – 2016-04-27 · Healthy
What this study did
NCT03508635 · Corcept Therapeutics
2014-09 – 2015-12 · Healthy
What this study did

Competitive landscape

This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Cushing's Syndrome: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Relacorilant (Lifyorli): this drugPhase 3Small moleculeGlucocorticoid receptorPartial signal
NCT04308590: Change in Average 24-hour SBP (Baseline and Week 22): Relacorilant -5.56 mm Hg (95% CI -10.459 to -0.659) vs Placebo -2.89 mm Hg (95% CI -6.794 to 1.006) missed
Albuterol / Budesonide (Airsupra)
Approved(overall)
CombinationBeta-2 adrenergic receptor, Glucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Beclomethasone (QVAR)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Betamethasone Dipropionate Emollient Spray (Sernivo)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Budesonide (Entocort EC)
Approved(overall)
Small moleculeGlucocorticoid receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
Budesonide (Ortikos)
ApprovedUS marketing discontinued (overall)
—Glucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Budesonide (targeted-Release) (TARPEYO / Nefecon)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Budesonide (Uceris Rectal Foam)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Budesonide MMX (Uceris)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Ciclesonide (Alvesco)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Dexamethasone
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Dexamethasone (Dextenza)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Fluticasone Furoate (Arnuity Ellipta)
Approved(overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)
Approved(overall)
Small moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Fluticasone Furoate / Vilanterol (Breo Ellipta)
Approved(overall)
Small moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Fluticasone Propionate
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Fluticasone Propionate / Salmeterol (Advair HFA)
Approved(overall)
CombinationGlucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Halobetasol Propionate Foam (Lexette)
ApprovedUS marketing discontinued (overall)
Small moleculeGlucocorticoid receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Halobetasol Propionate Lotion (Bryhali)
Approved(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Hydrocortisone (Cortenema)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Hydrocortisone Acetate (Cortifoam)
Approved(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Mifepristone (Korlym)ApprovedSmall moleculeProgesterone receptor; Glucocorticoid receptorWeak signalNo reviewed efficacy summary in this indication
Lodotra (Rayos)
US approval withdrawn(overall)
—Glucocorticoid receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
ClofutribenPhase 2Small molecule11-beta-HSD1not yet gradedNo reviewed efficacy summary in this indication
Dazucorilant
Phase 2(overall)
Small moleculeGlucocorticoid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Miricorilant
Phase 2(overall)
Small moleculeGlucocorticoid receptor
Partial signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Relacorilant (Lifyorli) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Cushing's SyndromeActive not recruiting
Est. primary completion 2026-12 · NCT03604198 · CT.gov ↗
What to watch
2027 (3)
September 2027 (1)
Phase 2Adenocarcinoma, Carcinoma, Pancreatic DuctalRecruiting
Est. primary completion 2027-09 · NCT07259317 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Prostate Cancer, Prostate AdenocarcinomaRecruiting
Est. primary completion 2027-10-01 · NCT05726292 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-12 · NCT06906341 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Phase 1/2Type 2 Diabetes, HypercortisolismNot yet recruiting
Est. primary completion 2028-12-15 · NCT07925801 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 2Recurrent or Metastatic Cervical CancerNot yet recruiting
Est. primary completion 2030-12 · NCT07763496 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(7)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

17 December 2026FDA action datePDUFA date for the relacorilant NDA resubmission in Cushing's syndrome
US, FDA · Corcept Therapeutics Incorporated · Source ↗

Recent

17 June 2026Filing submittedCorcept resubmits the relacorilant NDA in Cushing's syndrome to the FDA
US, FDA · Corcept Therapeutics Incorporated · Source ↗
27 May 2026Complete response letterFDA issued a complete response letter
US, FDA · Source ↗
March 2026ApprovalFDA approves Lifyorli for platinum-resistant ovarian cancer
US, FDA · Source ↗
22 January 2026Topline resultPhase 3 ROSELLA of relacorilant met its overall survival primary endpoint
Corcept Therapeutics · Source ↗
31 December 2025Complete response letterFDA issues complete response letter for relacorilant in hypercortisolism
US, FDA · Corcept Therapeutics · Source ↗
December 2024Filing submittedCorcept submits the relacorilant NDA in endogenous hypercortisolism
US, FDA · Source ↗